Advaxis is a biotechnology company developing immunotherapies that enlist the body’s own immune system to fight cancer. We discover, develop and make better medicines through innovative sciences.
Advaxis To Present Poster Entitled “Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy” At Society For Immunotherapy Of Cancer Annual Meeting
Advaxis Reports Fiscal Year 2018 Financial Results And Provides a Business Update
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted For Multiple Presentations At 2018 Keystone Symposia Conference On Cancer Immunotherapies: Combinations